HaniHassounMD

Associate Professor of Medicine, Cornell University-Weill Medical College

Overview of Dr. Hassoun

Dr. Hani Hassoun is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and New York-Presbyterian Hospital. He received his medical degree from Pierre and Marie Curie University and has been in practice 34 years. Dr. Hassoun accepts several types of health insurance, listed below. He is one of 62 doctors at Memorial Sloan Kettering Cancer Center and one of 10 doctors at NYC Health + Hospitals / Bellevue who specialize in Hematology. He also speaks multiple languages, including French. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(910) 623-0942

Education & Training

St Elizabeth's Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1991
Brigham and Women's HospitalResidency, Internal Medicine, 1983 - 1986
Pierre and Marie Curie University Class of 1983

Certifications & Licensure

NY State Medical License 2002 - 2026
NJ State Medical License 2024 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2008-2014

Clinical Trials

Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis Start of enrollment: 2007 Feb 01
Completed
Phase 2
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L Start of enrollment: 2008 Dec 10
Completed
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2011 May 09
Completed
Phase 2
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Start of enrollment: 2011 Jun 24
Completed
Not Applicable
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance Start of enrollment: 2011 Oct 28
Completed
Phase 2
Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma Start of enrollment: 2013 Aug 06
Completed
Phase 2
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2016 Dec 28
Completed
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) Start of enrollment: 2023 Oct 16
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Up...
Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, Kinga Hosszu, Sean M Devlin
Journal of Clinical Oncology. 2024-12-04
Evaluating serum free light chain ratio as a biomarker in multiple myeloma.
Theresia Akhlaghi, Kylee Maclachlan, Neha Korde, Sham Mailankody, Alexander Lesokhin
Haematologica. 2024-10-03
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody
Blood Cancer Journal. 2024-09-19

Abstracts/Posters

Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) ...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
Hani Hassoun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Other Languages

French

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment